InVivoMab anti-mouse CSF1 BE0204-R005mg from Bio X Cell | Biocompare.com

Supplier Images

InVivoMab anti-mouse CSF1

Be the first to write a review!

Citations:

Supplier Page from
Bio X Cell for
InVivoMab anti-mouse CSF1

The InVivoMab anti-mouse CSF1 Antibody from Bio X Cell is a Rat Monoclonal antibody to CSF1. This antibody recognizes Mouse antigen. The InVivoMab anti-mouse CSF1 Antibody has been validated for the following applications: In Vivo, and Block/Neutralize/Inhibit.

Description

Bio X Cell InVivoMAb anti-mouse CSF1 Monoclonal Antibody has the following reported applications: in vivo CSF1 neutralization. It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMab anti-mouse CSF1
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0204-R005mg
Quantity5 mg
Applicationsin vivo CSF1 neutralization
ConcentrationLot specific,typically between 4-11 mg/ml
Conjugate/TagUnconjugated
TargetCSF1
IsotypeIgG1, κ
Clone5A1
Hostrat
NCBI Full Gene Namecolony stimulating factor 1 (macrophage)
NCBI Gene AliasesBAP025, Csfm, MCSF, Mhdabap25, PG-M-CSF, op
ClonalityMonoclonal
ImmunogenPurified mouse CSF-1
Antibody TypePrimary Antibody
Purity>95%, Determined by SDS-PAGE
FormatPBS, pH 8.0, Contains no stabilizers or preservatives
Research AreaCytokine and Chemokine

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) CD47 blockade triggers T cell-mediated destruction of immunogenic tumorsNature medicineOctober 1, 2015Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, Xu H, Peng H, Fu YX, Xu MM.

(2) DC-SIGN(+) Macrophages Control the Induction of Transplantation ToleranceImmunityJune 16, 2015Conde P, Rodriguez M, van der Touw W, Jimenez A, Burns M, Miller J, Brahmachary M, Chen HM, Boros P, Rausell-Palamos F, et al.

(3) Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cellsCancer cellNovember 10, 2014Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM.

(4) CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer modelsCancer researchSeptember 15, 2014Zhu Y, Knolhoff BL, Meyer MA, Nywening TM, West BL, Luo J, Wang-Gillam A, Goedegebuure SP, Linehan DC, DeNardo DG.

(5) JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemiaMolecular cancer therapeuticsNovember 1, 2009Manthey CL, Johnson DL, Illig CR, Tuman RW, Zhou Z, Baker JF, Chaikin MA, Donatelli RR, Franks CF, Zeng L, et al.

Be the First to Write a Review!